In particular, the HSP70–peptide complexes from the fused DC–tumor hybrid cells exhibited the stronger immunogenicity and augmented killing of tumor cells as compared with the effects of HSP70–peptide complexes from the unfused (tumor) cells [241]. The gene discussed is HSPA1A; the disease is neoplasm.